Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Phase 1b, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability, and the Efficacy of Si-544 in Adults With Psoriasis Vulgaris or Psoriatic Arthritis

NCT06191042 is registered in ClinicalTrials.gov with selectION Therapeutics GmbH as lead sponsor.

NCT NCT06191042
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06191042 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Phase 1b, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability, and the Efficacy of Si-544 in Adults With Psoriasis Vulgaris or Psoriatic Arthritis
Lead sponsor
selectION Therapeutics GmbH
Phase
Phase 1
Overall status
Completed
Start date
January 22, 2024
Completion date
June 23, 2025
Enrollment
45 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

psoriasis vulgaris, psoriatic arthritis